NASDAQ:TVRD | Insider Transactions — Page 3 | Tvardi Therapeutics, Inc.

TVRD Insider Transactions — Page 3

252 retained open-market purchase and sale rows from SEC Forms 3, 4 and 5, newest first. This page shows rows 201–252; provenance stays internal.

Insider profileRoleDateTransactionSharesPrice
Slagel DeanDirector2016-01-05Sale31,224.0$17.01
Slagel DeanDirector2016-01-05Sale31,224.0$17.01
Menzaghi Frederique Ph.D.VP-Research & Development2016-01-04Sale6,000.0$16.8
Slagel DeanDirector2015-12-31Sale12,776.0$17.0
Slagel DeanDirector2015-12-31Sale12,776.0$17.0
Menzaghi Frederique Ph.D.VP-Research & Development2015-12-01Sale6,000.0$16.21
Menzaghi Frederique Ph.D.VP-Research & Development2015-11-02Sale6,000.0$14.26
Menzaghi Frederique Ph.D.VP-Research & Development2015-10-01Sale1,500.0$14.44
Menzaghi Frederique Ph.D.VP-Research & Development2015-10-01Sale4,500.0$13.79
Menzaghi Frederique Ph.D.VP-Research & Development2015-09-01Sale7,000.0$18.63
Schoell JosefChief Financial Officer2015-08-18Purchase3,000.0$22.1
Stauffer Joseph WilliamChief Medical Officer2015-08-04Purchase2,000.0$18.6
Menzaghi Frederique Ph.D.VP-Research & Development2015-08-03Sale7,000.0$21.41
Menzaghi Frederique Ph.D.VP-Research & Development2015-07-01Sale7,000.0$12.22
Lewis Michael EChief Scientific Advisor2015-07-01Sale7,262.0$11.66
Lewis Michael EChief Scientific Advisor2015-06-01Sale7,262.0$9.5
Slagel DeanDirector2015-05-19Sale32,266.0$10.0
Slagel DeanDirector2015-05-18Sale82,945.0$10.04
Slagel DeanDirector2015-05-15Sale73,600.0$10.0
Lewis Michael EChief Scientific Advisor2015-05-01Sale7,262.0$10.64
Lewis Michael EChief Scientific Advisor2015-04-01Sale7,262.0$9.9
Lewis Michael EChief Scientific Advisor2015-03-02Sale7,262.0$10.11
Schoell JosefChief Financial Officer2015-02-17Sale15,000.0$10.96
Lewis Michael EChief Scientific Advisor2015-02-02Sale7,262.0$10.6
VOGELBAUM MARTINDirector2014-02-05Purchase225,818.0$11.0
RUCH JOSHUATenPercentOwner2014-02-05Purchase225,818.0$11.0
KAIROUZ HABIBTenPercentOwner2014-02-05Purchase225,818.0$11.0
LESCHLY MARKTenPercentOwner2014-02-05Purchase225,818.0$11.0
Rho Capital Partners LLCTenPercentOwner2014-02-05Purchase225,818.0$11.0
RHO Ventures VI LPTenPercentOwner2014-02-05Purchase225,818.0$11.0
RMV VI, L.L.C.TenPercentOwner2014-02-05Purchase225,818.0$11.0
CHAMPSI FARAHTenPercentOwner2014-02-05Purchase2,547.0$11.0
PENHOET EDWARDTenPercentOwner2014-02-05Purchase2,547.0$11.0
HURWITZ EDWARDDirector,TenPercentOwner2014-02-05Purchase2,547.0$11.0
ALTA BIOPHARMA PARTNERS III LPTenPercentOwner2014-02-05Purchase2,547.0$11.0
ALTA BIOPHARMA MANAGEMENT III LLCTenPercentOwner2014-02-05Purchase2,547.0$11.0
ALTA EMBARCADERO BIOPHARMA PARTNERS III LLCTenPercentOwner2014-02-05Purchase2,547.0$11.0
ALTA BIOPHARMA PARTNERS III GMBH & CO BETEILIGUNGS KGTenPercentOwner2014-02-05Purchase2,547.0$11.0
CHAMPSI FARAHTenPercentOwner2014-02-05Purchase6,940.0$11.0
PENHOET EDWARDTenPercentOwner2014-02-05Purchase6,940.0$11.0
HURWITZ EDWARDDirector,TenPercentOwner2014-02-05Purchase6,940.0$11.0
ALTA BIOPHARMA PARTNERS III LPTenPercentOwner2014-02-05Purchase6,940.0$11.0
ALTA BIOPHARMA MANAGEMENT III LLCTenPercentOwner2014-02-05Purchase6,940.0$11.0
ALTA EMBARCADERO BIOPHARMA PARTNERS III LLCTenPercentOwner2014-02-05Purchase6,940.0$11.0
ALTA BIOPHARMA PARTNERS III GMBH & CO BETEILIGUNGS KGTenPercentOwner2014-02-05Purchase6,940.0$11.0
CHAMPSI FARAHTenPercentOwner2014-02-05Purchase103,330.0$11.0
PENHOET EDWARDTenPercentOwner2014-02-05Purchase103,330.0$11.0
HURWITZ EDWARDDirector,TenPercentOwner2014-02-05Purchase103,330.0$11.0
ALTA BIOPHARMA PARTNERS III LPTenPercentOwner2014-02-05Purchase103,330.0$11.0
ALTA BIOPHARMA MANAGEMENT III LLCTenPercentOwner2014-02-05Purchase103,330.0$11.0
ALTA EMBARCADERO BIOPHARMA PARTNERS III LLCTenPercentOwner2014-02-05Purchase103,330.0$11.0
ALTA BIOPHARMA PARTNERS III GMBH & CO BETEILIGUNGS KGTenPercentOwner2014-02-05Purchase103,330.0$11.0